New Screening Strategy for Epigenetic Targets: European ScreeningPort Forms Strategic Alliance with Hypha
ESP recently established an epigenetic enzyme profiling panel covering sirtuins and histone deacetylase targets. These high throughput assays have already been shown to perform well in screens against known drugs and lead-like synthetic compounds.
This new collaboration, which builds on the service offerings of both companies, will expose the MycoDiverseTM natural products library to multiple therapeutic targets implicated in a range of epigenetic-linked diseases including cancer, asthma, neurodegenerative and metabolic disorders. ESP know–how is positioned at the forefront of epigenetic assay design. The technology employs a luminescence-based readout, which while more resistant to the artefacts associated with fluorescence based assays, is also extremely sensitive at low enzyme concentrations, allowing rapid and cost effective assay development and screening.
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.